Skip to content
Search

Latest Stories

IPL to begin as per schedule despite Covid-19 worries in India

THE surge in new Covid-19 cases could yet scupper plans to host the Indian Premier League (IPL) in bio-secure bubbles at six venues across the country, starting on Friday (9) in Chennai and climaxing at the world's largest cricket stadium in Ahmedabad on May 30.

Last year's delayed tournament was shifted to the United Arab Emirates but the 14th edition returns to India, where the coronavirus situation has worsened significantly in recent weeks.


The Indian cricket board (BCCI), however, is bullish about the chances of pulling it off.

"We did it successfully in Dubai last year. We are confident we are going to do it again this time," BCCI chief Sourav Ganguly told Reuters.

Champions Mumbai Indians, captained by Rohit Sharma, and Virat Kohli's Royal Challengers Bangalore get the eight-team tournament going at M A Chidambaram Stadium on Friday.

Both teams have already been hit by Covid-19 cases in their camps, however, raising questions over the effectiveness of the health protections afforded to the cricketers by the bubble.

Players will be well compensated for their stint in India as, even without ticket sales, the IPL was still worth $6.19 billion last year, according to financial consultancy firm Duff & Phelps. That was down from $6.78 billion in 2019.

The BCCI would have been left with a $542 million hole in its coffers if it had cancelled its flagship event last year but ended up with record TV and digital viewership.

With curfews currently in force in many Indian states, the IPL can be expected to surpass last year's viewership numbers with cricket fans in the world's second most populous nation set to be glued to TV sets and electronic devices.

Bhairav Shanth, the managing director of global sport consulting firm ITW, said interest among advertisers has been high this year and predicted a windfall for broadcasters because of the "tremendous" pull of the IPL.

"For a tournament that is having another edition barely six months removed from the last one, the appetite has been fantastic," Shanth said. "In 2020, there was a slight dip in deal volume and sizes.

"But now as we see this edition occupy the prime summer slot with nothing else significant on TV to compete against, we have already seen new partners come on board in the league at a premium of 30-40 per cent from what it was last year."

Even the recent spike in the number of Covid-19 cases has not deterred the cream of world cricket from heading to India, where the T20 World Cup will also be held later this year.

Rajasthan Royals all-rounder Ben Stokes has been delighted to see so many of his England colleagues plying their trade in recent editions of the IPL.

"Being constantly exposed to that is a huge benefit to us as a team, especially with the T20 World Cup coming up at the end of the year in India," he told Sky Sports.

"It's a great chance for the English guys to get more experience in these conditions."

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less